Women's Health Weekly
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Women's Health Weekly
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Breast Cancer
Enzyme expression ratio is a prognostic indicator in tamoxifen-treated patients
April 14th, 2005
The ratio of 17 beta-hydroxysteroid dehydrogenase types 1 and 2 expression is a prognostic indicator for recurrence-free survival of breast cancer patients treated with tamoxifen, according to a study from Sweden. "The 17beta hydroxysteroid dehydrogenase (17HSD) enzymes are involved in the local regulation of sex steroids. The 17HSD type 1 enzyme catalyzes the interconversion of the weak estrone (E1) to the more potent estradiol (E2), whereas 17HSD type 2 catalyzes the oxidation of E2 to E1," explained C. Gunnarsson and colleagues, Linkoping University of Hospital. In this study, they "[correlated] the expression of these enzymes in the tumor with...
Source: Women's Health Weekly (2005-04-14)
|
